Furthermore, simvastatin has shown a greater capacity to reduce von Willebrand factor (vWF) levels, underscoring its crucial role in managing SCD-associated hypercoagulability (Akaba et al., 2020; Sahebkar et al., 2016). The gene discussed is VWF; the disease is Schnyder corneal dystrophy.